Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin
Condition(s):Ototoxicity, Drug-InducedLast Updated:March 6, 2024Not yet recruiting
Include Studies Not Open or Pending
Condition(s):Ototoxicity, Drug-InducedLast Updated:March 6, 2024Not yet recruiting
Condition(s):Vestibular Schwannoma; OtotoxicityLast Updated:July 7, 2023Recruiting
Condition(s):Cancer; Ototoxicity, Drug-Induced; Quality of Life; Hearing DisordersLast Updated:January 9, 2024Recruiting
Condition(s):Ototoxicity, Drug-InducedLast Updated:January 18, 2024Recruiting
Condition(s):Head and Neck Cancer Survivors; Cancer of the Head and Neck SurviorsLast Updated:October 24, 2023Recruiting
Condition(s):Ototoxic Hearing LossLast Updated:April 14, 2023Recruiting
Condition(s):Ototoxic Hearing LossLast Updated:September 6, 2023Recruiting
Condition(s):Aminoglycoside Toxicity; Aminoglycoside-Induced Hearing Loss; Hearing Loss; Video GamesLast Updated:May 12, 2023Recruiting
Condition(s):Hearing Loss OtotoxicLast Updated:March 3, 2023Recruiting
Condition(s):Cisplatin Adverse Reaction; Cisplatin Nephrotoxicity; Cisplatin Induced Peripheral Neuropathy; Cancer Patients; Cisplatin OtotoxicityLast Updated:March 7, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.